Skip to main content

Table 2 Safety, from first dose of study drug through end of study (Week 84)

From: A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

 

Placebo

(n = 145)

Quilizumab

150 mg Q

(n = 145)

Quilizumab

450 mg Q

(n = 145)

Quilizumab

300 mg M

(n = 143)

All Quilizumab

(n = 433)

Any AE

114 (78.6 %)

110 (75.9 %)

108 (74.5 %)

103 (72.0 %)

321 (74.1 %)

Serious AE

12 (8.3 %)

11 (7.6 %)

10 (6.9 %)

16 (11.2 %)

37 (8.5 %)

Grade 3 AE or higher

21 (14.5 %)

28 (19.3 %)

30 (20.7 %)

24 (16.8 %)

82 (18.9 %)

Grade 2 AE or higher

86 (59.3 %)

78 (53.8 %)

80 (55.2 %)

82 (57.3 %)

240 (55.4 %)

Infections and infestations

76 (52.4 %)

73 (50.3 %)

71 (49.0 %)

68 (47.6 %)

212 (49.0 %)

Parasitic infections

0

0

0

1 (0.7 %)

1 (0.2 %)

Serious infections

3 (2.1 %)

3 (2.1 %)

1 (0.7 %)

2 (1.4 %)

6 (1.4 %)

Injection site reactions

12 (8.3 %)

10 (6.9 %)

13 (9.0 %)

7 (4.9 %)

30 (6.9 %)

Serious injection site reactions

0

0

0

0

0

AE leading to treatment withdrawal

1 (0.7 %)

4 (2.8 %)

1 (0.7 %)

1 (0.7 %)

6 (1.4 %)

Malignancies

0

2 (1.4 %)

2 (1.4 %)

0

4 (0.9 %)

Deaths

0

0

0

0

0

  1. AE adverse event, M monthly, Q quarterly